Generics - Diabetes, Markets & Marketing

Filter

Popular Filters

Mylan extends deal with Biocon to biosimilar insulins, as Actavis pulls out of JV

14-02-2013

US generic drugmaker Mylan (Nasdaq: MYL) said yesterday that it has entered into a definitive agreement…

ActavisBioconBiotechnologyDiabetesEli LillyGenericsHumalogLantusLicensingMarkets & MarketingMylan LaboratoriesNovo NordiskNovoLogSanofi

US nephrologists expect rapid adoption of USA's first biosimilars - epoetin alfa

09-10-2012

More than 60% of surveyed nephrologists in the USA expect to begin prescribing biosimilar epoetin alfa…

BiotechnologyDiabetesGenericsMarkets & MarketingNephrology and Hepatology

Most US and European physicians believe automatic substitution of biosimilars is a bad idea

05-09-2012

Specialist physicians surveyed in the USA and Europe are generally opposed to pharmacy-level automatic…

BiotechnologyDiabetesEuropeGenericsMarkets & MarketingNorth America

Ranbaxy debuts authorized Actos generic in USA, followed by Teva and Mylan

20-08-2012

The US subsidiary of Ranbaxy Laboratories (AB: BO), India's largest drugmaker, has launched authorized…

ActoplusMetActosDiabetesGenericsMarkets & MarketingMylan LaboratoriesNorth AmericaRanbaxy LaboratoriesRegulationTakeda PharmaceuticalsTeva Pharmaceutical Industries

New Actavis/Bioton alliance aims to shake up diabetes market

31-01-2012

Icelandic generics drugmaker Actavis and Poland’s Bioton (WSE: BIO) have formed a joint venture…

ActavisBiotonDiabetesGenericsMarkets & MarketingMergers & AcquisitionsPharmaceutical

Back to top